Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

Table 3 Analyses of factors related to sustained virologic response: Univariate and multivariate effectiveness analysis

	ITT						mITT
	Univariate			Multivariate			Univariate			Multivariate
	OR	95%CI	P value	OR	95%CI	P value	OR	95%CI	P value	OR	95%CI	P value
Previous response1
R	2.6	1.8-3.7	0.000	1.8	1.09-3.1	0.022	2.4	1.6-3.5	0.000	1.9	1.1-3.3	0.019
PR	0.9	0.6-1.3	NS	0.9	0.5-1.7	NS	0.9	0.6-1.3	NS	0.8	0.4-1.6	NS
NR	0.4	0.2-0.5	0.000	0.6	0.37-0.9	0.330	0.5	0.3-0.7	0.000	0.7	0.39-1.1	NS
IL28B2
CC	3.6	2.2-5.9	0.000	3.07	1.5-5.9	0.001	3.2	1.9-5.4	0.000	3.0	1.4-6.0	0.002
CT	1.8	1.2-2.6	0.003	1.6	1.001-2.6	0.049	1.8	1.2-2.8	0.004	1.6	0.9-2.7	NS
Fibrosis3
Non-F4	2.1	1.6-2.8	0.000	2.0	1.33-3.0	0.001	2.26	1.7-3.04	0.000	2.1	1.4-3.3	0.000
Treatment4
TVR	1.7	1.3-2.1	0.000	1.5	1.02-2.2	0.038	1.1	0.9-1.5	NS	1.1	0.7-1.7	NS
LogGGT	0.19	0.12-0.3	0.000	0.3	0.18-0.6	0	0.2	0.15-0.23	0.000	0.4	0.2-0.7	0.004
LogViral load	0.8	0.6-1.003	NS	0.7	0.5-0.99	0.048	0.8	0.6-1.003	NS	0.7	0.4-1.1	NS

¹TN;

²TT;

³F4;

⁴BOC. TN: Treatment-naïve patients; R: Relapsers; PR: Partial responders; NR: Null responders; BOC: Boceprevir; ITT: Intention-to-treatment; mITT: Modified intention-to-treatment.